Climb Bio (CLYM) Amortizatization of Intangibles (2021 - 2026)
Climb Bio (CLYM) reported Amortizatization of Intangibles of $305000.0 for Q1 2026, down 54.41% on a YoY basis from $669000.0 in Q1 2025, and down 40.31% quarter-over-quarter from $511000.0 in Q4 2025.
Climb Bio (CLYM) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Climb Bio has reported Amortizatization of Intangibles for 6 years, with the latest figure at $305000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 54.41% year-over-year to $305000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 40.13% YoY), and the FY2025 full-year result was $2.3 million, up 200.4% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $305000.0, down from $511000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $753000.0 in Q3 2023, with the low at -$193000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $365250.0 across 5 years, with a median of $445500.0 in 2022.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 975.71% — and 2024, when it sank 87.17%.
- Climb Bio's Amortizatization of Intangibles stood at $400000.0 in 2022, then retreated by 13.5% to $346000.0 in 2023, then surged by 51.73% to $525000.0 in 2024, then fell by 2.67% to $511000.0 in 2025, then plunged by 40.31% to $305000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $305000.0 (Q1 2026), $511000.0 (Q4 2025), and $523000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | 305,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305,000.00 |
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 511,000.00 |
| Dec 31, 2025 | 511,000.00 |
| Sep 30, 2025 | 523,000.00 |
| Sep 30, 2025 | 523,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 669,000.00 |
| Mar 31, 2025 | 669,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Sep 30, 2023 | 753,000.00 |
| Sep 30, 2023 | 753,000.00 |